GSK exec lauds 'great start' to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59

Thanks to respiratory syncytial virus (RSV) shot Arexvy’s new label expansion into a slightly younger pool of adults, GSK is more confident than ever that its vaccine will be able to conquer the competition.

On Friday, the FDA approved Arexvy for RSV prevention in adults ages 50 to 59 who are at increased risk of developing RSV disease.